Data MATRIX Introduces AI-operated Patient Survival Assessment Tool
A feature of the presented tool for predictive analysis of Real-World Data (RWD) is the ability to collect and analyze data on different patient cohorts. Machine algorithms collect information about patients from medical records received from prevention and treatment facilities, pharmaceutical companies, and researchers in 29 regions of the Russian Federation.
As a result, pharmaceutical and biotech companies will have a legally compliant provider of RWD derived from millions of EHRs. This will aim to contribute to the overall knowledge base on drugs efficacy and safety, including those of vaccines.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
